AEGiS-11IAC: The combination of DNA and peptide vaccines induces strong immunities against HIV-1 in both humoral and CMI.

11th International AIDS Conference


Vancouver, British Columbia — July 7-12, 1996

Print this Article


The combination of DNA and peptide vaccines induces strong immunities against HIV-1 in both humoral and CMI.

Int Conf AIDS 1996 Jul 7-12; 11:6 (abstract no. Mo.A.151)
Hamajima K, Fukushima J, Kaneko T, Bukawa H, Tsuji T, Xin KQ, Asakura Y, Okuda K, Nishioka K, Okuda K; Yokohama City University, Yokohama, Japan. Fax: 81-45-787-2509.

OBJECTIVE: We have reported that the synthetic peptide vaccine (VC1) against HIV induced a high level of neutralizing antibodies for various HIV isolates, and the DNA vaccine against HIV induced prolonged high CTI level. In the present study, we examined whether the combination of DNA vaccine and the peptide vaccine could induce a high level immune responses against HIV-1 in both humoral and CTI responses. Materials and

METHODS: HIV-1 strains, IIIB and SF2, and three clinical isolates from Japan were used for nuetrilizing assay, and mice, rabbits and Macaca fuscata were used for immunization. VC1 was the cycled form of the V3 loop peptides, which consisted of PND consensus sequences of Japan, IIII and Thai B, CD4 binding sites and a Gag region peptide (HGP-30). The HIV-1 DNA vaccine, a mixture of pCREV DNA and pCMV 160 IIIB DNA was directly inoculated into the above animal muscles.

RESULTS: The antisera derived from VC1 or DNA plus VC1 vaccination inhibited the growth of the five HIV isolates. In addition, DNA vaccination or DNA plus VC1 vaccination induced a high level of CTL. Discussion and

CONCLUSIONS: Our results demonstrate that combination of our DNA vaccine and peptide vaccine can induce high levels of both CMI and humoral immunities. This vaccination design may be one of the ideal HIV-1 vaccines. However, HIV challenge in vivo is necessary for the final conclusion.

Keywords: AEGIS, HIV-1, AIDS Vaccines, Vaccines, Subunit, HIV Antibodies, HIV Antigens, Vaccines, DNA, HIV, Vaccines, Synthetic, HIV Infections, Immunity, HIV Envelope Protein gp160, Peptides, Vaccination, Immunization, Japan, HIV p17 antigen peptide HGP-30, Animal, Mice, Rabbits, immunology, ICA11

960707
MoA151

Copyright © 1996 - International AIDS Society (IAS). Reproduction of this abstract (other than one copy for personal reference) must be cleared through the IAS.